Untargeted Metabolomics Unveils Metabolic Biomarkers in HFpEF

Untargeted Metabolomics Unveils Metabolic Biomarkers in HFpEF | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Untargeted Metabolomics Unveils Metabolic Biomarkers in HFpEF Dongqin Duan, Muyashaer Abudurexiti, Refukaiti Abuduhalike, Salamaiti Aimaier, and 1 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7082748/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Heart failure with preserved ejection fraction (HFpEF) is a complex condition linked to metabolic disturbances. This study aimed to identify plasma metabolic signatures in HFpEF patients using untargeted metabolomic profiling. Methods We analyzed data from 30 HFpEF patients and 30 matched healthy controls. Untargeted metabolomic profiling via UHPLC-MS/MS was conducted on venous blood to identify metabolic differences. Initial analyses included principal component analysis (PCA), partial least squares-discriminant analysis (PLS-DA), and hierarchical clustering to detect differing compound groups. Receiver operating characteristic (ROC) curve analysis and pathway enrichment were performed to identify dysregulated genes. Finally, enzyme-linked immunosorbent assay (ELlSA) was used to validate the serum levels of selected metabolites. Results A total of 124 significantly different metabolites were identified (VIP > 1.0, FC > 1.2 or < 0.833, P < 0.05). Lipids and lipid-like molecules were notably altered in HFpEF patients. KEGG enrichment analysis indicated these metabolites were primarily involved in tryptophan metabolism. Hierarchical clustering showed distinct compound levels between groups. ROC curve analysis revealed PC 18:1–20:5 (AUC: 0.833) and PC 18:1–18:1 (AUC: 0.824) as key metabolites. ELlSA validation confirmed that serum Kynurenine and IAA levels were significantly elevated in HFpEF patients compared to HCs (p < 0.05). HFpEF metabolomics tryptophan metabolism indole kynurenine biomarker Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 1. Introduction Heart failure (HF) is a complex syndrome and often the end-stage of various cardiovascular diseases. Heart failure with preserved ejection fraction (HFpEF) is a subtype that affects up to half of the approximately 65 million HF patients worldwide ( 1 ) . However, its pathophysiology remains poorly understood. Among the diverse factors contributing to HFpEF, metabolic disturbances have emerged as critical elements that influence the disease trajectory ( 2 ) . These disturbances reflect a complex interplay between genetic predispositions, comorbid conditions, and environmental factors, ultimately affecting cardiac and systemic homeostasis ( 3 ) . Metabolic alterations have been implicated in the development and progression of various cardiovascular diseases, including heart failure ( 4 – 6 ) . Nonetheless, the majority of these studies utilized animal models, leading to a paucity of data on human HFpEF metabolism. Concurrently, interest in metabolic impairment as a potential contributing factor to the onset and progression of HFpEF has increased ( 1 , 7 – 9 ) .Therefore, investigating the plasma metabolic profile of HFpEF patients could provide valuable insights into the underlying mechanisms and potentially identify novel biomarkers for early diagnosis and targeted therapies ( 10 ) . In recent years, developments in analytical techniques, particularly ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry(UHPLC-MS/MS), have greatly enhanced the comprehensive and accurate profiling of metabolites in biological samples.High sensitivity, selectivity, and throughput are provided by UHPLC-MS/MS, rendering it an ideal platform for metabolomic analysis ( 11 , 12 ) .This study employed untargeted metabolomics to compare metabolite expression profiles between HFpEF patients and healthy controls to uncover new insights and potential therapeutic targets for HFpEF. 2. Materials and methods 2.1. Participants and clinical sample collection HFpEF Study Population: Samples were collected from 30 HFpEF patients and 30 healthy controls at the First Affiliated Hospital of Xinjiang Medical University between March 1, 2023, and July 31, 2023. All adult subjects provided written informed consent to participate in the study. Diagnosis Criteria: Patients were diagnosed with HFpEF based on the following consensus criteria (4, 5, 13) : symptoms and signs of exertional dyspnea (New York Heart Association class II or III), HF with left ventricular ejection fraction (LVEF) ≥ 50%, and at least two of the following: (1) elevated NT-proBNP (N-terminal pro-B-type natriuretic peptide) ≥125 pg/mL; (2) structural heart disease or diastolic dysfunction on echocardiography; and (3) E/e’≥9. Exclusion criteria: Patients with a history of congenital heart disease, LVEF < 40%, HF with mid-range EF (40–50%), hypertrophic cardiomyopathy, cardiac transplantation, constrictive pericarditis, severe valvular disease, or infiltrative or restrictive cardiomyopathy were excluded (1, 14) ; Ethical Approval: This study received approval from the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University. Informed consent was obtained from each participant. Sample collection: Venous blood samples were collected in the morning prior to breakfast after an overnight fast. Following centrifugation at 300 rpm for 10 minutes ,the supernatant was harvested and stored at -80℃ until analysis. 2.2. Plasma sample preparation Sample Processing: Plasma samples obtained in EDTA tubes were promptly processed. Each 100 μL sample was resuspended in pre-chilled 80%methanol and then vortexed thoroughly. After 5 minutes of incubation on ice and 20 minutes of centrifugation at 15，000 × g at 4 ° C， the supernatants were collected and diluted with LC-MS grade water to achieve a final concentration of 53%methanol. LC‒MS/MS analysis: The diluted samples were further centrifuged for 20 min at 15,000 × g and 4°C. The supernatants were then subjected to LC‒MS/MS analysis. Quality Control: Quality control (QC) samples, comprising equal volumes of mixtures of experimental samples, were prepared to monitor the chromatography‒mass spectrometry system balance, system stability, and instrument status throughout the experiment. Blank samples were also added to remove background ions. 2.3. UHPLC-MS/MS analysis The UHPLC-MS/MS analyses were performed using a Vanquish UHPLC system(Thermo Fisher， Germany)，combined with either an Orbitrap Q ExactiveTM HF or an Orbitrap Q ExactiveTM HF-X mass spectrometer(Thermo Fisher， Germany)at Novogene Co.，Ltd. (Beijing，China). Samples were injected onto a Hypersil Gold column(100 × 2.1 mm，1.9 μm)and analyzed at a flow rate of 0.2Ml/min over a 12-minute linear gradient . The positive ion mode eluents included 0.1% formic acid in water (eluent A) and methanol (eluent B), while the negative ion mode eluents consisted of 5 mM ammonium acetate (pH 9.0, eluent A) and methanol (eluent B). The elution profile was as follows: 1.5 min with 2% B; 3 min with 2-85% B; 10 min with 85-100% B; 10 min with 100-2% B; and 12 min with 2% B. The Q Exactive TM HF mass spectrometer was operated under the following conditions: positive/negative ion mode, 3.5 kV spray voltage, 320°C capillary temperature, 350°C aux gas heater temperature, 10 L/min aux gas flow rate, 35 psi sheath gas flow rate, and an S-lens RF level of 60. 2.4. Data processing and metabolite identification The raw data from UHPLC-MS/MS were analysed using Compound Discoverer 3.3(CD3.3，ThermoFisher)for peak alignment，picking，andquantitation. Key parameters included:peak area correction with the first QC，mass tolerance of 5 ppm，signal intensity tolerance of 30%，and minimum intensity.Peak intensities were then adjusted to the total spectral intensity.This normalized data was used to predict molecular formulas based on additive ions，molecular ion peaks，and fragment ions. Peaks were matched with mzCloud(https: //www. mzcloud. org/)，mzVault，andMassList databases for correct qualitative and relative quantitative results. Statistical analyses were conducted using R(R version R-3.4.3)，Python(version 2.7.6)，and CentOS(release 6.6). For non-normally distributed data, relative peak areas were standardized using the formula: raw quantitation value / (sum of sample metabolite quantitation / sum of QC1 metabolite quantitation). Compounds with CVs of relative peak areas in QC samples exceeding 30% were excluded，leading to the final identification and relative quantification of metabolites. 2.4. Data Analysis Metabolite annotation in plasma samples was performed with the KEGG (https://www.genome.jp/kegg/pathway.html), LIPIDMaps (http://www.lipidmaps.org/) and HMDB (https://hmdb.ca/metabolites) databases. Using metaX, partial least squares discriminant analysis (PLS-DA) and principal component analysis (PCA) were conducted. Univariate regression (t-test) was used to determine significant differences (P value). Metabolites meeting the criteria of VIP >1 and P value< 0.05 and fold change≥2 or FC≤0.5 were classified as differentially expressed. Volcano plots generated by ggplot2 in R facilitated the selection of metabolites based on log2(FC) and -log10(P value). 2.5 Enzyme-linked immunosorbent assay (ELISA) for clinical blood samples Serum samples obtained from patients newly diagnosed with HFpEF. Patients were given a fast before the sample was taken in order to lessen the effect of dietary variables. In order to avoid coagulation，blood samples were taken in vacuum-sealed tubes containing EDTA. After centrifugation at 3000 rpm for 10 min, the supernatant was carefully collected and stored at -80 'C for subsequent analysis. Serum levels were measured by ELISA kit Kynurenine (Human kynurenine ELISA Kit YS04739B Yaji-Biotechnology), Indole-3-acetic acid (Human Indole-3-acetic acid ELISA Kit L0511 Yaji-Biotechnology), according to the manufacturer's instructions. 3. Results 3.1. Baseline features of participants Table 1 compares the basic characteristics of the HFpEF and HC groups. The groups were matched for age and sex. Compared with the two groups, the HFpEF group presented significantly greater levels of IL-6, LP(b), NT-ProBNP, and Cr and lower levels of TC, LDL, and HDL, with notable incidences of hypertension (70%, p =0.004), CAD (56.7%, p <0.001), and DM (46.7%, p <0.001). However, lower levels of TC and LDL in HFpEF patients might be attributable to lipid-lowering treatments. Other parameters, such as CRP, TG, LP(a), E/e`, LVED, and SAA, were not significantly different between the groups (P>0.05). 3.2. Quality control of untargeted metabolic profiling Considering the influence of exogenous factors on the metabolome, ensuring instrumental stability and a normal signal response during metabolite detection, critical QC was performed via Pearson correlation analysis between the QC samples and principal component analysis (PCA). Pearson correlation coefficients (R2) among the QC samples were close to 1 in both ion modes (Figure 1A, B), indicating high stability and data quality. 3.3. Metabolite pathways and classification annotations Comparative analysis of metabolic signatures in untargeted metabolomics between the HFpEF and HC groups under the ESI+ and ESI− modes. The statistical analysis of the identified chemically classified metabolites revealed that lipid metabolites constituted the majority in both the positive and negative ion modes, accounting for 37.35% and 54.06%, respectively (Figure 1C, D). Subsequently, to understand the functional characteristics and classification of different metabolites, metabolite pathway, and classification annotations were performed using major databases such as KEGG, HMDB, and LIPID MAPS (Figure 2A-D). 3.4. Identification of differentially expressed metabolites The investigation of alterations in various metabolites within the HFpEF group necessitated the application of multivariate statistical methodologies, specifically PCA and PLS-DA, to elucidate the relationship between biological features and metabolomics. Unsupervised PCA, a conventional approach in pattern recognition, was employed to scrutinize the distribution of the HFpEF group and remove outlier data. PCA revealed the distinctiveness of the two groups based on PC1 and PC. Concurrently, disparities in metabolite profiles between the HFpEF and HC groups were observed (Figure 3A). Furthermore, supervised PLS-DA multivariate analysis corroborated significant differences between the two groups, revealing distinct clustering of the HFpEF and HC groups (Figure 3B). Additionally, the results of the permutation test strongly indicated that the original model was valid (R2 intercept=0.72, Q2 intercept=−0.44, Figure 3C), suggesting that the PLS-DA model did not overfit. These results indicate a favorable model fit and predictive performance. To elucidate the characteristics of plasma metabolites within the HFpEF group and identify metabolites confidently associated with HFpEF, distinctions between the ESI+ and ESI- modes were made based on VIP (variable importance in projection, VIP) > 1.0, FC > 1.2 or FC < 0.833 and a P value< 0.05. Overall, 993 differential compounds were identified from plasma samples, 124 of which reached statistical significance. Among these, 87 metabolites exhibited upregulation, with fold changes reaching up to 2.77, and 15 metabolites displayed downregulation, with fold changes as low as 0.48. A lollipop chart was generated to visualize the distribution of the top 20 differentially expressed metabolites (DEMs) between the two groups (Figure 3D). Notably, the downregulation of specific phospholipids may point to altered lipid metabolism and energy use in HFpEF patients. Additionally, a heatmap was constructed to depict the significantly different plasma metabolites between the HFpEF group and the HC group (Figure 3E). Notably, the significantly upregulated metabolites in the HFpEF group included lipids and amino acids, whereas the significantly downregulated metabolites included phosphatidylcholines (PCs) and phosphatidylethanolamine (PEs) (Table S1). 3.5. Significance of differentially abundant metabolites in diagnosing HFpEF Univariate ROC curves were generated for each metabolite to assess their diagnostic potential for HFpEF. In this investigation, As shown in Figure 4A, C, E, G that PC 18:1-20:5 (AUC:0.833), PC 18:1-18:1 (AUC:0.824), PC 36:2 (AUC:0.781), and PC 0-40:8 (AUC:0.721) could serve as biomarkers for HFpEF. These metabolites also exhibited the highest significance, with PC 18:1-20:5 (AUC:0.833) and PC 18:1-18:1 (AUC:0.824) acetate demonstrating superior area under the curve (AUC) values. Furthermore，the expression levels of these metabolites were much lower than those in the HC group(Figure 4B、D、F、H)，This might suggest a significant difference in the metabolism of this lipid component between the groups. 3.6. Pathway enrichment analysis Analysis of the KEGG network diagram (Figure 5) revealed prominent activation of the tryptophan (Trp) pathway in the examined plasma samples. Compared with those in healthy controls, the levels of key regulatory metabolites within this pathway, such as indole-3-acetate and L-kynurenine, were significantly increased (p < 0.05). These metabolites are shown in green in the network diagram，signifying their elevated expression. The Trp pathway is suggested by these results as a possible therapeutic target for HFpEF. 3.7. Clinical correlations of selected metabolites Spearman’s correlation analysis was employed to examine the relationship between metabolites and NT-proBNP. The 20 most significant metabolites identified through univariate regression demonstrated a moderate-to-high correlation with NT-proBNP, LVEF, LVED, E/e’(Figure 6). PC 18:1_20:5(r=-0.48, p =0.48) exhibited a predominantly negative correlation with NT-proBNP and E/e’ (Figure 6A-C).This observation suggests that altered lipid metabolism, likely a consequence of metabolic stress, may play a critical role in the disease progression of HFpEF cases. 3.8 Validation of tryptophan metabolite alterations in HFpEF patients by ELISA In the human serum validation conducted via enzyme-linked immunosorbent assay (ELISA), the concentrations of kynurenine (Figure 7A) and indole-3-acetic acid (Figure 7B) were significantly elevated in the HFpEF group. These findings corroborate the metabolomics results, indicating that metabolites along the tryptophan metabolic pathway are markedly altered in patients with HFpEF relative to healthy controls (P < 0.05). 4. Discussion Metabolic impairment significantly influences the onset and progression of HFpEF. However, the detailed metabolic pathogenesis of HFpEF remains largely unexplored. Previous investigations into the metabolic profiles of HFpEF have utilized various metabolomics approaches, including NMR spectroscopy, liquid chromatography‒mass spectrometry (LC‒MS), and gas chromatography‒mass spectrometry (GC–MS) (10, 15-18) . In this study, offers a comprehensive metabolic profiling of HFpEF patients compared to healthy controls, utilizing UHPLC-MS/MS technology. Untargeted metabolomics testing identified differentially abundant metabolite expression profiles in the plasma of HFpEF patients and HC, highlighting distinct plasma metabolic characteristics in HFpEF compared to HC. Initially, the most notable changes in HFpEF relative to HC were in amino acids, peptides, analogs, and lipids, followed by alterations in organoheterocyclic compounds. KEGG enrichment and pathway impact analysis indicated significant differences between the two groups. Notably, pathways such as Tryptophan metabolism was significantly altered, suggesting potential critical impact on HFpEF progression. Additionally, 124 significantly different metabolites were selected, which PC 18:1-20:5, PC 18:1-18:1 as potential biomarkers. Metabolic disturbances in HFpEF patients HFpEF is associated with oxidative stress and inflammation, impaired lipid metabolism, increased collagen production, disturbed lipid metabolism, and reduced nitric oxide signaling (18) . Diabetes and obesity are risk factors for HFpEF and contribute to left ventricular (LV) diastolic dysfunction, and cardiac lipotoxicity is believed to play a role in its pathogenic mechanism. Excessive fatty acids (FAs) are stored after consumption (19, 20) , and various lipids act as signaling molecules in insulin resistance and inflammatory pathways (21, 22) , thereby influencing cardiovascular disease onset. Glycerophospholipids, including PC, PE, and lysophospholipids, are crucial for maintaining cell membrane structure and signal transduction. In HFrEF patients, the serum levels of PC, lysoPC, lysoPE, and other substances significantly decrease, indicating that a disruption in phospholipid metabolism is linked to advanced age, poor clinical conditions, and impaired muscle oxidative metabolism (23) . Recent studies have also revealed a significant decrease in the serum levels of PC and lysoPC metabolites in HFpEF patients (2) . According to our study，there were significant decreases in glycerophospholipid levels(PC 18:1_20:5，PC 18:1_18:1，PC 36:2，PC O-40:8，PC 19:2_20:4，PC 20:3_20:4，Pure 29:2，Pent 20:4，C 18:2_20:3，Pure 40:5，Pure 39:2，PO4:11，Pure 18:2_20:4，PO8:17:5，POD:2，PAGE:16:1_22:4，PEO-18:2_20:4)levels of the plasma of HFpEF patients as opposed to those in the HC plasma. These glycerophospholipids play an important role in maintaining cell membrane integrity and signal transduction, and abnormal levels of these lipids can lead to myocardial metabolic disorders induced by lipotoxicity (24) . Furthermore, our study revealed a significant upregulation of phosphatidylcholines (PCs) and phosphatidylethanolamines (PEs), consistent with previous findings in HFpEF patients (10, 18) . This finding supports the notion that disturbed lipid metabolism due to metabolic stress is likely crucial for HFpEF progression. Understanding the complexities of lipid metabolism in HFpEF could provide valuable insights for developing targeted treatments. Strategies focusing on modulating lipid uptake, enhancing lipid oxidation, and restoring mitochondrial function may help mitigate disturbances and improve cardiac function in HFpEF patients. Tryptophan Metabolism as a Novel Pathway in HFpEF Tryptophan (Trp), an essential amino acid, serve as a precursor for various biochemical reactions in the human body, including the synthesis of serotonin, glycols, glucocorticoids, and diabetic drugs (25) . Trp metabolism is closely associated with various cardiovascular diseases, with increasing research examining its relationship with Heart Failure (HF) (26-28) . Trp metabolism primarily involves pathways such as kynurenine(Kyn), 5-hydroxytryptamine, and indole, generating bioactive compounds that regulate functions like metabolism, inflammation, neurological function and immune responses (29) . The gut microbiota significantly affects Trp metabolism by transforming it into various molecules, including indole and its derivatives (30) . Recent studies have linked disturbances in the Trp metabolism pathway and the resulting Kyn upregulation to myocardial infarction and atherosclerosis (31, 32) . Trp is metabolized predominantly via the kynurenine pathway, which is activated by inflammatory cytokines (33) . HFpEF is characterized by chronic low-grade inflammation, which can exacerbate myocardial stress and endothelial dysfunction. The kyn pathway metabolites have pro-inflammatory and oxidative properties that may exacerbate the cardiovascular burden in HFpEF patients. Research indicates that disruptions in tryptophan metabolism are associated with several cardiovascular risk factors, such as hypertension, atherosclerosis, and diabetes, all of which are prevalent in HFpEF populations (25) . A study suggested that elevated levels of kynurenine pathway metabolites could serve as biomarkers for worsening heart failure symptoms and poor outcomes in HFpEF patients (18) . In this study, metabolomic analysis revealed significant alterations in the tryptophan metabolic pathway. Further validation using enzyme-linked immunosorbent assay (ELISA) indicated that serum levels of kynurenine and indole-3-acetic acid (IAA) were markedly elevated in patients with HFpEF. These findings suggest that dysregulation of tryptophan metabolism, particularly the increases in kynurenine and IAA, may play a pivotal role in the pathogenesis and progression of HFpEF. Kynurenine, a metabolite jointly regulated by the gut microbiota and the immune system, has been extensively documented to be closely associated with vascular inflammation, atherosclerosis, and myocardial hypertrophy (34, 35) . Mechanistic studies (36) have demonstrated that kynurenine can activate the aryl hydrocarbon receptor (AHR), thereby promoting myocardial remodeling and fibrosis. Additionally, kynurenine exhibits prominent pro-inflammatory and vasoregulatory effects, further implicating its involvement in the development of cardiovascular diseases (37) . Recent research also highlights its role in modulating inflammatory responses in relation to cancer and chronic illnesses, providing multidimensional evidence of its systemic effects (38, 39) . As a tryptophan-derived uremic toxin, indole-3-acetic acid (IAA) accumulates in patients with chronic kidney disease and has been linked to impaired cardiovascular function and increased mortality risk (40) . In vivo studies, such as those by Ramya et al. (41) have demonstrated that IAA induces cardiotoxicity by activating inflammatory pathways and promoting myocardial fibrosis, subsequently impairing cardiovascular performance. The elevated IAA levels observed in HFpEF patients suggest that it may contribute to disease progression via inflammatory and remodeling pathways, intensifying cardiac dysfunction. Previous investigations have confirmed associations between kynurenine, IAA, and cardiovascular diseases. The potential pathogenic mechanisms may involve kynurenine’s activation of immune-inflammatory pathways, leading to fibrosis and myocardial remodeling, and IAA’s role as a uremic toxin that alters the cardiovascular microenvironment, inducing inflammation and fibrosis, ultimately impairing cardiac function. These metabolites may exert synergistic or interconnected effects in the pathogenesis of HFpEF, influencing disease onset and progression. Despite existing evidence linking kynurenine and IAA to cardiovascular pathology, their precise mechanistic roles in HFpEF remain to be fully elucidated. Future research employing multi-level in vivo and in vitro approaches, with larger sample sizes and more targeted analyses, is necessary to validate these findings and clarify the underlying pathogenic mechanisms. Such studies could facilitate the development of these metabolites as biomarkers for early diagnosis and disease monitoring, as well as novel therapeutic targets for HFpEF management. 5. Conclusion In conclusion, metabolomics analyses have identified significant alterations in glycerophospholipid metabolism and the tryptophan pathway in HFpEF, with subsequent validation using enzyme-linked immunosorbent assay (ELISA) confirming elevated levels of kynurenine and indole-3-acetic acid in the serum of HFpEF group . Both glycerophospholipid metabolism and the tryptophan pathway play significant roles in regulating cardiovascular health and disease. 6. Study Limitations There were some shortcomings of the current study to be noted. First, the sample sizes of the HFpEF and HC groups were relatively modest, necessitating a larger, prospective validation cohort to substantiate the identified metabolites. Additionally, the metabolomic profile provides an overview of metabolic disturbances potentially influenced by confounders such as acute illnesses, other disease states, and medication usage. Consequently, it remains uncertain whether the metabolic disturbances identified are exclusively associated with HFpEF syndrome. The majority of recent metabolomics research involving heart failure patients relies on blood samples;however，Hahn et al. [1] recently reported that changes in plasma metabolite contents between HFpEF and HFrEF patients may not accurately reflect myocardial metabolic characteristics. This finding underscores the importance of using myocardial tissue directly for metabolomics analysis. Overall, the small sample size in this study could impact the robustness of our results. The metabolome of each individual is highly sensitive to various endogenous and exogenous factors, such as age, sex, diet, environment, geographical location, genetics, and time of day [44] (42) . Therefore, future studies should focus on the spontaneous screening of HFpEF patients and the validation of these findings. The current results could be further enriched and corroborated by integrating metabolomics research on plasma and feces. Declarations Acknowledgments Not Applicable Ethics approval and consent to participate The study was conducted following the ethical standards outlined in the Declaration of Helsinki (1964) and its subsequent revisions. This experiment has been approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University, and the approval number of this study is 2022B03023-4. All adult subjects provided written informed consent to participate in the study. The individual provided written informed consent to share information about his medical condition and any related images .The Committee's review ensures that the research meets all relevant ethical standards and local/national guidelines. Conflicts of Competing Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest. Funding This work was supported by the Key R&D Program of Xinjiang Uygur Autonomous Region [Grant No. 2022B03023-4]. Authors’ contributions AM participated in the review and editing. MA, RA performed experiments and analyzed data. DD and MA wrote the manuscript. SA and DD Data curation, Writing- Original draft preparation. All authors read and approved the final manuscript. Data Availability All data generated or analyzed during this study are included in this paper. Further enquiries can be directed to the corresponding author. Clinical trial number Not applicable References Hahn VS, Petucci C, Kim MS, Bedi KC, Wang HH, Mishra S, et al. Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction. Circulation. 2023;147(15):1147-61. Ferro F, Spelat R, Valente C, Contessotto P. Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction. Biomolecules. 2022;12(7):22. Henkens M, Remmelzwaal S, Robinson EL, van Ballegooijen AJ, Aizpurua AB, Verdonschot JAJ, et al. Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. European Journal of Heart Failure. 2020;22(9):1586-97. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure. 2020;22(3):391-412. Anker SD, Usman MS, Anker MS, Butler J, Böhm M, Abraham WT, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association and the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. European Journal of Heart Failure. 2023;25(7):936-55. Hunter WG, Kelly JP, McGarrah RW, Khouri MG, Craig D, Haynes C, et al. Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. J Am Heart Assoc. 2016;5(8):27. Schiattarella GG, Altamirano F, Tong D, French KM, Villalobos E, Kim SY, et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature. 2019;568(7752):351-+. Palazzuoli A, Tramonte F, Beltrami M. Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature. Biomolecules. 2023;13(1). Bekfani T, Bekhite M, Neugebauer S, Derlien S, Hamadanchi A, Nisser J, et al. Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker. Cells. 2022;11(10):13. Zordoky BN, Sung MM, Ezekowitz J, Mandal R, Han B, Bjorndahl TC, et al. Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction. PLoS One. 2015;10(5):19. Deng YC, Wang JQ, Zhang AN, Zhu ZJ, Ren SP, Zhang CL, et al. Metabolomics Mechanism and Lignin Response to Laxogenin C, a Natural Regulator of Plants Growth. Int J Mol Sci. 2022;23(6):12. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011;6(7):1060-83. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal. 2021;42(48):4901. Hahn VS, Knutsdottir H, Luo X, Bedi K, Margulies KB, Haldar SM, et al. Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction. Circulation. 2021;143(2):120-34. Bedi KC, Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, et al. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation. 2016;133(8):706-16. Lanfear DE, Gibbs JJ, Li J, She RC, Petucci C, Culver JA, et al. Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients. JACC-Heart Fail. 2017;5(11):823-32. Piatek K, Feuerstein A, Zach V, da Conceicao CR, Beblo A, Belyavskiy E, et al. Nitric oxide metabolites: associations with cardiovascular biomarkers and clinical parameters in patients with HFpEF. Esc Heart Failure. 2022;9(6):3961-72. Hage C, Löfgren L, Michopoulos F, Nilsson R, Davidsson P, Kumar C, et al. Metabolomic Profile in HFpEF vs HFrEF Patients. J Card Fail. 2020;26(12):1050-9. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):12. Leggat J, Bidault G, Vidal-Puig A. Lipotoxicity: a driver of heart failure with preserved ejection fraction? Clin Sci. 2021;135(19):2265-83. Pickens CA, Vazquez AI, Jones AD, Fenton JI. Obesity, adipokines, and C-peptide are associated with distinct plasma phospholipid profiles in adult males, an untargeted lipidomic approach. Sci Rep. 2017;7:14. Kojta I, Chacinska M, Blachnio-Zabielska A. Obesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance. Nutrients. 2020;12(5):19. Marcinkiewicz-Siemion M, Ciborowski M, Ptaszynska-Kopczynska K, Szpakowicz A, Lisowska A, Jasiewicz M, et al. LC-MS-based serum fingerprinting reveals significant dysregulation of phospholipids in chronic heart failure. J Pharm Biomed Anal. 2018;154:354-63. Rodriguez-Cuenca S, Pellegrinelli V, Campbell M, Oresic M, Vidal-Puig A. Sphingolipids and glycerophospholipids - The "ying and yang" of lipotoxicity in metabolic diseases. Prog Lipid Res. 2017;66:14-29. Wyant GA, Moslehi J. Expanding the Therapeutic World of Tryptophan Metabolism. Circulation. 2022;145(24):1799-802. Gong X, Sun ZH, Huang ZY, Zhou Q, Yu ZQ, Chen XY, et al. Circulating metabolite profiles to predict response to cardiac resynchronization therapy. BMC Cardiovasc Disord. 2020;20(1):10. Masenga SK, Povia JP, Lwiindi PC, Kirabo A. Recent Advances in Microbiota-Associated Metabolites in Heart Failure. Biomedicines. 2023;11(8):22. Ravid JD, Kamel MH, Chitalia VC. Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease. Nat Rev Nephrol. 2021;17(6):402-16. Xue C, Li GL, Zheng QX, Gu XY, Shi QM, Su YS, et al. Tryptophan metabolism in health and disease. Cell Metab. 2023;35(8):1304-26. Zhang J, Zhu SW, Ma N, Johnston LJ, Wu CD, Ma X. Metabolites of microbiota response to tryptophan and intestinal mucosal immunity: A therapeutic target to control intestinal inflammation. Med Res Rev. 2021;41(2):1061-88. Kowalik K, Miekus N, Baczek T. Small Molecules Originated from Tryptophan and their Clinical Significance as Potential Biomarkers. Comb Chem High Throughput Screen. 2022;25(11):1809-17. Laurans L, Venteclef N, Haddad Y, Chajadine M, Alzaid F, Metghalchi S, et al. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nat Med. 2018;24(8):1113-+. Liu G, Chen S, Zhong J, Teng KL, Yin YL. Crosstalk between Tryptophan Metabolism and Cardiovascular Disease, Mechanisms, and Therapeutic Implications. Oxidative Med Cell Longev. 2017;2017:5. Paeslack N, Mimmler M, Becker S, Gao ZL, Khuu MP, Mann A, et al. Microbiota-derived tryptophan metabolites in vascular inflammation and cardiovascular disease. Amino Acids. 2022;54(10):1339-56. Wang YH, Song J, Yu K, Nie D, Zhao CC, Jiao LP, et al. Indoleamine 2,3-Dioxygenase 1 Deletion-Mediated Kynurenine Insufficiency Inhibits Pathological Cardiac Hypertrophy. Hypertension. 2023;80(10):2099-111. Shi BZ, Zhang XY, Song ZY, Dai ZH, Luo K, Chen B, et al. Targeting gut microbiota-derived kynurenine to predict and protect the remodeling of the pressure-overloaded young heart. Sci Adv. 2023;9(28):14. Wang YT, Liu HZ, McKenzie G, Witting PK, Stasch JP, Hahn M, et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med. 2010;16(3):279-U72. Adams S, Braidy N, Bessesde A, Brew BJ, Grant R, Teo C, et al. The Kynurenine Pathway in Brain Tumor Pathogenesis. Cancer Res. 2012;72(22):5649-57. Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: Tryptophan's metabolites in exercise, inflammation, and mental health. Science. 2017;357(6349):8. Nayak S, Boopathi S, Chandrasekar M, Panda SP, Manikandan K, Chitra V, et al. Indole-3-acetic acid exposure leads to cardiovascular inflammation and fibrosis in chronic kidney disease rat model. Food Chem Toxicol. 2024;192:13. Nayak S, Boopathi S, Chandrasekar M, Yamini B, Chitra V, Almutairi BO, et al. Indole-3 acetic acid induced cardiac hypertrophy in Wistar albino rats. Toxicol Appl Pharmacol. 2024;486:12. Miao XL, Chen JP, Su YY, Luo JY, He Y, Ma J, et al. Plasma metabolomic analysis reveals the therapeutic effects of Jiashen tablets on heart failure. Front Cardiovasc Med. 2022;9:15. Table Additional Declarations No competing interests reported. Supplementary Files TableS1.doc Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7082748","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":488011020,"identity":"0f44a269-c9f9-45ee-9963-90c0b4248298","order_by":0,"name":"Dongqin Duan","email":"","orcid":"","institution":"First Affiliated Hospital of Xinjiang Medical University","correspondingAuthor":false,"prefix":"","firstName":"Dongqin","middleName":"","lastName":"Duan","suffix":""},{"id":488011021,"identity":"22c316d2-8083-47a1-b93b-443c0834323a","order_by":1,"name":"Muyashaer Abudurexiti","email":"","orcid":"","institution":"First Affiliated Hospital of Xinjiang Medical University","correspondingAuthor":false,"prefix":"","firstName":"Muyashaer","middleName":"","lastName":"Abudurexiti","suffix":""},{"id":488011022,"identity":"fd299084-6d12-493e-882d-a8bdcfa6cd8a","order_by":2,"name":"Refukaiti Abuduhalike","email":"","orcid":"","institution":"First Affiliated Hospital of Xinjiang Medical University","correspondingAuthor":false,"prefix":"","firstName":"Refukaiti","middleName":"","lastName":"Abuduhalike","suffix":""},{"id":488011023,"identity":"e7e20f6f-1e7d-427c-b01d-bd784b6f97e6","order_by":3,"name":"Salamaiti Aimaier","email":"","orcid":"","institution":"First Affiliated Hospital of Xinjiang Medical University","correspondingAuthor":false,"prefix":"","firstName":"Salamaiti","middleName":"","lastName":"Aimaier","suffix":""},{"id":488011024,"identity":"ab48a249-ea72-4d64-afc4-1dc0ce45215d","order_by":4,"name":"Ailiman Mahemuti","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA/ElEQVRIiWNgGAWjYDACZgYGgwQwg7nhAJCSY2NvP0CsFkawFmM+njMJxNrH2AAiE+dJOBjgVWdwnPdAwYOaO3b97YyNh27U3Elvk2BIYPhRsQ2nFslmvgSDhGPPkmccZmw4nHPsWW6bdOMBxp4zt3Fq4WfmMTBIYDuczADWwnY4t03mQAIzYxtuLWxgLf8OJ8uDtfw7nM4mkWCAVwvYlsS2w3YGIC25bYcTCGqRbAZp6TucYAjW0nfYsA0YyAfx+cXg/Bkzwx/fDtvLnT98+HPOt8Py8u3tBx/8qMCtBeQdUDQkNiALHcCnHgiYHwAJewKKRsEoGAWjYCQDAHm/XH25vgSEAAAAAElFTkSuQmCC","orcid":"","institution":"First Affiliated Hospital of Xinjiang Medical University","correspondingAuthor":true,"prefix":"","firstName":"Ailiman","middleName":"","lastName":"Mahemuti","suffix":""}],"badges":[],"createdAt":"2025-07-09 10:23:15","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7082748/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7082748/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":87347855,"identity":"9b964326-59d4-49a2-acf8-21ea4e26404c","added_by":"auto","created_at":"2025-07-23 02:49:20","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":70267,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eThe quality control of untargeted metabolomic profiling\u003c/strong\u003e. (A, B) Pearson correlation analysis between QC samples: the coefficient (R2) values were both nearly 1 under the positive (A) or negative (B) polarity modes. (C, D) Metabolite class I categorical pie chart in the positive (C) and negative (D) ion modes.\u003c/p\u003e","description":"","filename":"1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7082748/v1/cdcaa013e7140a3cb66bb883.jpg"},{"id":87347856,"identity":"8787eb52-0068-45d4-b701-6f91f8958f28","added_by":"auto","created_at":"2025-07-23 02:49:20","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":110445,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMetabolic Pathways and Classification Annotations \u003c/strong\u003e(A, B) KEGG Pathway Annotation in the positive (A) and negative (B) ion modes. (C, D) HMDB classification annotation in the positive (C) and negative (D) ion modes. (E, F) LIPID MAPS classification annotation in the positive (E) and negative (F) ion modes.\u003c/p\u003e","description":"","filename":"2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7082748/v1/79be953a7344ff2bf062385f.jpg"},{"id":87347859,"identity":"37d12477-1c3d-46c7-a9af-26fb3b733636","added_by":"auto","created_at":"2025-07-23 02:49:21","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":78484,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMetabolic alterations in HFpEF and HC samples. \u003c/strong\u003ePCA 3D score plot for the data from HFpEF patients (black) and HCs (red) (A). PLS-D analysis of differentially abundant metabolites in the HFpEF and HC groups (B) and cross-validation plot (C) with a permutation test repeated 200 times. (D) Volcano plot (D) illustrating DEMs between the HFpEF and HC groups. (D) Hierarchical cluster analysis of DEMs between HFpEF patients and HCs.\u003c/p\u003e","description":"","filename":"3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7082748/v1/11acb48e1ccb0c7ed39e896b.jpg"},{"id":87347719,"identity":"c74823a9-e253-4be0-8f2b-d4092e0d6cb3","added_by":"auto","created_at":"2025-07-23 02:41:21","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":56676,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eReceiver operating characteristic (ROC) analysis of different metabolites.\u003c/strong\u003e (A) PC 18:1_20:5. (C) PC 18:1_18:1. (E) PC 36:2, (G) PC 0-40:8. Box plots of selected DEM concentrations between HFpEF patients (red) and HCs (green). (B) PC 18:1_20:5. (D) PC 18:1_18:1. (F) PC 36:2, (H) PC 0-40:8.\u003c/p\u003e","description":"","filename":"4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7082748/v1/2b728759f831f8b6b699471f.jpg"},{"id":87347718,"identity":"3bd8373c-487d-4c45-b2c4-f8c1c6c63a22","added_by":"auto","created_at":"2025-07-23 02:41:21","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":99585,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSignificantly changed pathways based on the enrichment analysis\u003c/strong\u003e. KEGG network diagram positive (A) and negative (B) ion modes. (Note: Red dots represent a metabolic pathway, yellow dots represent information about a substance-related regulatory enzyme, green dots represent a background substance of a metabolic pathway, purple dots represent information about a class of substance molecular modules, blue dots represent a chemical interaction reaction of a substance, and green squares represent differential substances obtained in this comparison).\u003c/p\u003e","description":"","filename":"5.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7082748/v1/da878b80f6329af1b18fe03a.jpg"},{"id":87348556,"identity":"bd23f0f4-81f2-45f0-8ee7-3b413fceb17f","added_by":"auto","created_at":"2025-07-23 02:57:21","extension":"jpg","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":74562,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eCorrelation analysis between DEMs and clinical indicators. (A) \u003c/strong\u003eCorrelation chord diagram. (Note: Chord width represents correlation strength; Chord border color stands for correlation, with red and blue representing positive and negative correlations, respectively). Correlation Sankey Diagram Analysis (B). (Note: The left side represents differentially abundant metabolites, while the right side represents NT-proBNP. The lines represent correlations, with red indicating positive correlation and blue indicating negative correlation).Corralation heatmap (C) . (Note: the transverse is the clinical indicators, the longitudinal is the differential metabolite, in the right legend, the correlation coefficient, the red the color, the stronger the positive correlation, the stronger the blue, the stronger the stronger the negative correlation, the higher the ellipse, the absolute value of the correlation, the asterisk (*) in the figure is P＜ 0.05).\u003c/p\u003e","description":"","filename":"6.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7082748/v1/608dfeb9d528fdad06b616c0.jpg"},{"id":87347857,"identity":"d7fb882b-7156-4489-8aa2-0ed08addfe53","added_by":"auto","created_at":"2025-07-23 02:49:21","extension":"jpg","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":50228,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eExpression level of Kynurenine and Indole-3-acetic acid in human serum\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe serum metabolite contents of the healthy group (n=38) and the disease group (n=40) were measured using commercially available ELISA kits. Values are mean ± standard error mean. p \u0026lt; 0.05 was considered statistically different. **P＜0.05\u003c/p\u003e","description":"","filename":"7.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7082748/v1/76a8ad2ded0219ea50f7c36e.jpg"},{"id":89002663,"identity":"a28a08d1-704f-4623-a182-4f20df88726e","added_by":"auto","created_at":"2025-08-13 15:38:51","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1606701,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7082748/v1/2a135663-3054-4d5d-b683-f5c50e181c14.pdf"},{"id":87347713,"identity":"465a0ce4-f940-4888-8dfa-2a3372e6c928","added_by":"auto","created_at":"2025-07-23 02:41:20","extension":"doc","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":51712,"visible":true,"origin":"","legend":"","description":"","filename":"TableS1.doc","url":"https://assets-eu.researchsquare.com/files/rs-7082748/v1/63eedf70367372dcbf88457c.doc"}],"financialInterests":"No competing interests reported.","formattedTitle":"Untargeted Metabolomics Unveils Metabolic Biomarkers in HFpEF","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eHeart failure (HF) is a complex syndrome and often the end-stage of various cardiovascular diseases. Heart failure with preserved ejection fraction (HFpEF) is a subtype that affects up to half of the approximately 65\u0026nbsp;million HF patients worldwide\u003csup\u003e(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/sup\u003e. However, its pathophysiology remains poorly understood. Among the diverse factors contributing to HFpEF, metabolic disturbances have emerged as critical elements that influence the disease trajectory\u003csup\u003e(\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e)\u003c/sup\u003e. These disturbances reflect a complex interplay between genetic predispositions, comorbid conditions, and environmental factors, ultimately affecting cardiac and systemic homeostasis\u003csup\u003e(\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e)\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003eMetabolic alterations have been implicated in the development and progression of various cardiovascular diseases, including heart failure\u003csup\u003e(\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e)\u003c/sup\u003e. Nonetheless, the majority of these studies utilized animal models, leading to a paucity of data on human HFpEF metabolism. Concurrently, interest in metabolic impairment as a potential contributing factor to the onset and progression of HFpEF has increased\u003csup\u003e(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan additionalcitationids=\"CR8\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e)\u003c/sup\u003e .Therefore, investigating the plasma metabolic profile of HFpEF patients could provide valuable insights into the underlying mechanisms and potentially identify novel biomarkers for early diagnosis and targeted therapies\u003csup\u003e(\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e)\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003eIn recent years, developments in analytical techniques, particularly ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry(UHPLC-MS/MS), have greatly enhanced the comprehensive and accurate profiling of metabolites in biological samples.High sensitivity, selectivity, and throughput are provided by UHPLC-MS/MS, rendering it an ideal platform for metabolomic analysis\u003csup\u003e(\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e)\u003c/sup\u003e .This study employed untargeted metabolomics to compare metabolite expression profiles between HFpEF patients and healthy controls to uncover new insights and potential therapeutic targets for HFpEF.\u003c/p\u003e"},{"header":"2. Materials and methods","content":"\u003cp\u003e\u003cstrong\u003e\u003cem\u003e2.1. Participants and clinical sample collection\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHFpEF Study Population: Samples were collected from 30 HFpEF patients and 30 healthy controls at the First Affiliated Hospital of Xinjiang Medical University between March 1, 2023, and July 31, 2023. \u0026nbsp;All adult subjects provided written informed consent to participate in the study.\u003c/p\u003e\n\u003cp\u003eDiagnosis Criteria: Patients were diagnosed with HFpEF based on the following consensus criteria\u003csup\u003e(4, 5, 13)\u003c/sup\u003e\u003csup\u003e:\u003c/sup\u003e symptoms and signs of exertional dyspnea (New York Heart Association class II or III), HF with left ventricular ejection fraction (LVEF) ≥ 50%, and at least two of the following: (1) elevated NT-proBNP (N-terminal pro-B-type natriuretic peptide) ≥125 pg/mL; (2) structural heart disease or diastolic dysfunction on echocardiography; and (3) E/e’≥9.\u003c/p\u003e\n\u003cp\u003eExclusion criteria: Patients with a history of congenital heart disease, LVEF \u0026lt; 40%, HF with mid-range EF (40–50%), hypertrophic cardiomyopathy, cardiac transplantation, constrictive pericarditis, severe valvular disease, or infiltrative or restrictive cardiomyopathy were excluded\u0026nbsp;\u003csup\u003e(1, 14)\u003c/sup\u003e;\u003c/p\u003e\n\u003cp\u003eEthical Approval: This study received approval from the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University. Informed consent was obtained from each participant.\u003c/p\u003e\n\u003cp\u003eSample collection: Venous blood samples were collected in the morning prior to breakfast after an overnight fast. Following centrifugation at 300 rpm for 10 minutes ,the supernatant was harvested and stored at -80℃ until analysis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003e2.2. Plasma sample preparation\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSample Processing: Plasma samples obtained in EDTA tubes were promptly processed. Each 100 μL sample was resuspended in pre-chilled 80%methanol and then vortexed thoroughly. After 5 minutes of incubation on ice and 20 minutes of centrifugation at 15，000 × g at 4 ° C，\u0026nbsp;the supernatants were collected and diluted with LC-MS grade water to achieve a final concentration of 53%methanol.\u003c/p\u003e\n\u003cp\u003eLC‒MS/MS analysis: The diluted samples were further centrifuged for 20 min at 15,000 × g and 4°C. The supernatants were then subjected to LC‒MS/MS analysis.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eQuality Control: Quality control (QC) samples, comprising equal volumes of mixtures of experimental samples, were prepared to monitor the chromatography‒mass spectrometry system balance, system stability, and instrument status throughout the experiment. Blank samples were also added to remove background ions.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003e2.3. UHPLC-MS/MS analysis\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe UHPLC-MS/MS analyses were performed using a Vanquish UHPLC system(Thermo Fisher，\u0026nbsp;Germany)，combined with either an Orbitrap Q ExactiveTM HF or an Orbitrap Q ExactiveTM HF-X mass spectrometer(Thermo Fisher，\u0026nbsp;Germany)at Novogene Co.，Ltd. (Beijing，China). Samples were injected onto a Hypersil Gold column(100\u0026nbsp;×\u0026nbsp;2.1 mm，1.9\u0026nbsp;μm)and analyzed at a flow rate of 0.2Ml/min over a 12-minute linear gradient . \u0026nbsp;The positive ion mode eluents included 0.1% formic acid in water (eluent A) and methanol (eluent B), while the negative ion mode eluents consisted of 5 mM ammonium acetate (pH 9.0, eluent A) and methanol (eluent B). The elution profile was as follows: 1.5 min with 2% B; 3 min with 2-85% B; 10 min with 85-100% B; 10 min with 100-2% B; and 12 min with 2% B. The Q Exactive\u003csup\u003eTM\u003c/sup\u003e HF mass spectrometer was operated under the following conditions: positive/negative ion mode, 3.5 kV spray voltage, 320°C capillary temperature, 350°C aux gas heater temperature, 10 L/min aux gas flow rate, 35 psi sheath gas flow rate, and an S-lens RF level of 60.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003e2.4. Data processing and metabolite identification\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe raw data from UHPLC-MS/MS were analysed using Compound Discoverer 3.3(CD3.3，ThermoFisher)for peak alignment，picking，andquantitation. Key parameters included:peak area correction with the first QC，mass tolerance of 5 ppm，signal intensity tolerance of 30%，and minimum intensity.Peak intensities were then adjusted to the total spectral intensity.This normalized data was used to predict molecular formulas based on additive ions，molecular ion peaks，and fragment ions. Peaks were matched with mzCloud(https: //www. mzcloud. org/)，mzVault，andMassList databases for correct qualitative and relative quantitative results. Statistical analyses were conducted using R(R version R-3.4.3)，Python(version 2.7.6)，and CentOS(release 6.6). For non-normally distributed data, relative peak areas were standardized using the formula: raw quantitation value / (sum of sample metabolite quantitation / sum of QC1 metabolite quantitation). Compounds with CVs of relative peak areas in QC samples exceeding 30% were excluded，leading to the final identification and relative quantification of metabolites.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003e2.4. Data Analysis\u0026nbsp;\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMetabolite annotation in plasma samples was performed with the KEGG (https://www.genome.jp/kegg/pathway.html), LIPIDMaps (http://www.lipidmaps.org/) and HMDB (https://hmdb.ca/metabolites) databases. Using metaX, partial least squares discriminant analysis (PLS-DA) and principal component analysis (PCA) were conducted. Univariate regression (t-test) was used to determine significant differences (P value). Metabolites meeting the criteria of VIP \u0026gt;1 and P value\u0026lt; 0.05 and fold change≥2 or FC≤0.5 were classified as differentially expressed. Volcano plots generated by ggplot2 in R facilitated the selection of metabolites based on log2(FC) and -log10(P value).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003e2.5 Enzyme-linked immunosorbent assay (ELISA) for clinical blood samples\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSerum samples obtained from patients newly diagnosed with HFpEF. Patients were given a fast before the sample was taken in order to lessen the effect of dietary variables. In order to avoid coagulation，blood samples were taken in vacuum-sealed tubes containing EDTA. After centrifugation at 3000 rpm for 10 min, the supernatant was carefully collected and stored at -80 'C for subsequent analysis. Serum levels were measured by ELISA kit Kynurenine (Human kynurenine ELISA Kit YS04739B Yaji-Biotechnology), Indole-3-acetic acid (Human Indole-3-acetic acid ELISA Kit L0511 Yaji-Biotechnology), according to the manufacturer's instructions.\u003c/p\u003e"},{"header":"3. Results","content":"\u003cp\u003e\u003cstrong\u003e\u003cem\u003e3.1. Baseline features of participants\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTable 1\u0026nbsp;compares the basic characteristics of the HFpEF and HC groups. The groups were matched for age and sex. Compared with the two groups, the HFpEF group presented significantly greater levels of IL-6, LP(b), NT-ProBNP, and Cr and lower levels of TC, LDL, and HDL, with notable incidences of hypertension (70%, \u003cem\u003ep\u003c/em\u003e=0.004), CAD (56.7%,\u0026nbsp;\u003cem\u003ep\u003c/em\u003e\u0026lt;0.001), and DM (46.7%,\u003cem\u003e\u0026nbsp;p\u003c/em\u003e\u0026lt;0.001). However, lower levels of TC and LDL in HFpEF patients might be attributable to lipid-lowering treatments. Other parameters, such as\u0026nbsp;CRP, TG, LP(a),\u0026nbsp;E/e`, LVED, and SAA, were not significantly different between the groups (P\u0026gt;0.05).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003e3.2. Quality control of untargeted metabolic profiling\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eConsidering the influence of exogenous factors on the metabolome, ensuring instrumental stability and a normal signal response during metabolite detection, critical QC was performed via Pearson correlation analysis between the QC samples and principal component analysis (PCA). Pearson correlation coefficients (R2) among the QC samples were close to 1 in both ion modes (Figure 1A, B),\u0026nbsp;indicating high stability and data quality.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003e3.3. Metabolite pathways and classification annotations\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eComparative analysis of metabolic signatures in untargeted metabolomics between the HFpEF and HC groups under the ESI+ and ESI− modes. The statistical analysis of the identified chemically classified metabolites revealed that lipid metabolites constituted the majority in both the positive and negative ion modes, accounting for 37.35% and 54.06%, respectively (Figure 1C, D). Subsequently, to understand the functional characteristics and classification of different metabolites, metabolite pathway, and classification annotations were performed using major databases such as KEGG, HMDB, and LIPID MAPS (Figure 2A-D).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003e3.4. Identification of differentially expressed metabolites\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe investigation of alterations in various metabolites within the HFpEF group necessitated the application of multivariate statistical methodologies, specifically PCA and PLS-DA, to elucidate the relationship between biological features and metabolomics. Unsupervised PCA, a conventional approach in pattern recognition, was employed to scrutinize the distribution of the HFpEF group and remove outlier data. PCA revealed the distinctiveness of the two groups based on PC1 and PC. Concurrently, disparities in metabolite profiles between the HFpEF and HC groups were observed (Figure 3A). Furthermore, supervised PLS-DA multivariate analysis corroborated significant differences between the two groups, revealing distinct clustering of the HFpEF and HC groups (Figure 3B). Additionally, the results of the permutation test strongly indicated that the original model was valid (R2 intercept=0.72, Q2 intercept=−0.44, Figure 3C), suggesting that the PLS-DA model did not overfit. These results indicate a favorable model fit and predictive performance.\u003c/p\u003e\n\u003cp\u003eTo elucidate the characteristics of plasma metabolites within the HFpEF group and identify metabolites confidently associated with HFpEF, distinctions between the ESI+ and ESI- modes were made based on VIP (variable importance in projection, VIP) \u0026gt; 1.0, FC \u0026gt; 1.2 or FC \u0026lt; 0.833 and a P value\u0026lt; 0.05. Overall, 993 differential compounds were identified from plasma samples, 124 of which reached statistical significance. Among these, 87 metabolites exhibited upregulation, with fold changes reaching up to 2.77, and 15 metabolites displayed downregulation, with fold changes as low as 0.48. A lollipop chart was generated to visualize the distribution of the top 20 differentially expressed metabolites (DEMs) between the two groups (Figure 3D). Notably, the downregulation of specific phospholipids may point to altered lipid metabolism and energy use in HFpEF patients. Additionally, a heatmap was constructed to depict the significantly different plasma metabolites between the HFpEF group and the HC group (Figure 3E). Notably, the significantly upregulated metabolites in the HFpEF group included lipids and amino acids, whereas the significantly downregulated metabolites included phosphatidylcholines (PCs) and phosphatidylethanolamine (PEs) (Table S1).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003e3.5. Significance of differentially abundant metabolites in diagnosing HFpEF\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUnivariate ROC curves were generated for each metabolite to assess their diagnostic potential for HFpEF. In this investigation, As shown in Figure 4A, C, E, G that PC 18:1-20:5 (AUC:0.833), PC 18:1-18:1 (AUC:0.824), PC 36:2 (AUC:0.781), and PC 0-40:8 (AUC:0.721) could serve as biomarkers for HFpEF. These metabolites also exhibited the highest significance, with PC 18:1-20:5 (AUC:0.833) and PC 18:1-18:1 (AUC:0.824) acetate demonstrating superior area under the curve (AUC) values. Furthermore，the expression levels of these metabolites were much lower than those in the HC group(Figure 4B、D、F、H)，This might suggest a significant difference in the metabolism of this lipid component between the groups.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003e3.6. Pathway enrichment analysis\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAnalysis of the KEGG network diagram (Figure 5) revealed prominent activation of the tryptophan (Trp) pathway in the examined plasma samples. Compared with those in healthy controls, the levels of key regulatory metabolites within this pathway, such as\u0026nbsp;indole-3-acetate\u0026nbsp;and\u0026nbsp;L-kynurenine, were significantly increased (p \u0026lt; 0.05). These metabolites are shown in green in the network diagram，signifying their elevated expression.\u0026nbsp;The Trp pathway is suggested by these results as a possible therapeutic target for HFpEF.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003e3.7. Clinical correlations of selected metabolites\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSpearman’s correlation analysis was employed to examine the relationship between metabolites and NT-proBNP. The 20 most significant metabolites identified through univariate regression demonstrated a moderate-to-high correlation with NT-proBNP, LVEF, LVED, E/e’(Figure 6).\u0026nbsp;PC 18:1_20:5(r=-0.48, \u003cem\u003ep\u003c/em\u003e=0.48)\u0026nbsp;exhibited a predominantly negative correlation with\u0026nbsp;NT-proBNP and\u0026nbsp;E/e’ (Figure 6A-C).This observation suggests that altered\u0026nbsp;lipid metabolism, likely a consequence of metabolic stress, may play a critical role in the disease progression of\u0026nbsp;HFpEF\u0026nbsp;cases.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003e3.8 Validation of tryptophan metabolite alterations in HFpEF patients by ELISA\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn the human serum validation conducted via enzyme-linked immunosorbent assay (ELISA), the concentrations of kynurenine (Figure 7A) and indole-3-acetic acid (Figure 7B) were significantly elevated in the HFpEF group. These findings corroborate the metabolomics results, indicating that metabolites along the tryptophan metabolic pathway are markedly altered in patients with HFpEF relative to healthy controls (P \u0026lt; 0.05).\u003c/p\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eMetabolic impairment significantly influences the onset and progression of HFpEF. However, the detailed metabolic pathogenesis of HFpEF remains largely unexplored. Previous investigations into the metabolic profiles of HFpEF have utilized various metabolomics approaches, including NMR spectroscopy, liquid chromatography‒mass spectrometry (LC‒MS), and gas chromatography‒mass spectrometry (GC–MS)\u003csup\u003e(10, 15-18)\u003c/sup\u003e\u003csup\u003e.\u003c/sup\u003e In this study, offers a comprehensive metabolic profiling of HFpEF patients compared to healthy controls, utilizing UHPLC-MS/MS technology. Untargeted metabolomics testing identified differentially abundant metabolite expression profiles in the plasma of HFpEF patients and HC, highlighting distinct plasma metabolic characteristics in HFpEF compared to HC.\u003c/p\u003e\n\u003cp\u003eInitially, the most notable changes in HFpEF relative to HC were in amino acids, peptides, analogs, and lipids, followed by alterations in organoheterocyclic compounds. KEGG enrichment and pathway impact analysis indicated significant differences between the two groups. Notably, pathways such as Tryptophan metabolism was significantly altered, suggesting potential critical impact on HFpEF progression. Additionally, 124 significantly different metabolites were selected, which PC 18:1-20:5, PC 18:1-18:1 as potential biomarkers.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eMetabolic disturbances in HFpEF patients\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHFpEF is associated with oxidative stress and inflammation, impaired lipid metabolism, increased collagen production, disturbed lipid metabolism, and reduced nitric oxide signaling\u0026nbsp;\u003csup\u003e(18)\u003c/sup\u003e. Diabetes and obesity are risk factors for HFpEF and contribute to left ventricular (LV) diastolic dysfunction, and cardiac lipotoxicity is believed to play a role in its pathogenic mechanism. Excessive fatty acids (FAs) are stored after consumption\u003csup\u003e(19, 20)\u003c/sup\u003e, and various lipids act as signaling molecules in insulin resistance and inflammatory pathways\u003csup\u003e(21, 22)\u003c/sup\u003e, thereby influencing cardiovascular disease onset.\u003c/p\u003e\n\u003cp\u003eGlycerophospholipids, including PC, PE, and lysophospholipids, are crucial for maintaining cell membrane structure and signal transduction. In HFrEF patients, the serum levels of PC, lysoPC, lysoPE, and other substances significantly decrease, indicating that a disruption in phospholipid metabolism is linked to advanced age, poor clinical conditions, and impaired muscle oxidative metabolism\u0026nbsp;\u003csup\u003e(23)\u003c/sup\u003e. Recent studies have also revealed a significant decrease in the serum levels of PC and lysoPC metabolites in HFpEF patients\u003csup\u003e(2)\u003c/sup\u003e. According to our study，there were significant decreases in glycerophospholipid levels(PC 18:1_20:5，PC 18:1_18:1，PC 36:2，PC O-40:8，PC 19:2_20:4，PC 20:3_20:4，Pure 29:2，Pent 20:4，C 18:2_20:3，Pure 40:5，Pure 39:2，PO4:11，Pure 18:2_20:4，PO8:17:5，POD:2，PAGE:16:1_22:4，PEO-18:2_20:4)levels of the plasma of HFpEF patients as opposed to those in the HC plasma. These glycerophospholipids play an important role in maintaining cell membrane integrity and signal transduction, and abnormal levels of these lipids can lead to myocardial metabolic disorders induced by lipotoxicity\u003csup\u003e(24)\u003c/sup\u003e. Furthermore, our study revealed a significant upregulation of phosphatidylcholines (PCs) and phosphatidylethanolamines (PEs), consistent with previous findings in HFpEF patients\u0026nbsp;\u003csup\u003e(10, 18)\u003c/sup\u003e. This finding supports the notion that disturbed lipid metabolism due to metabolic stress is likely crucial for HFpEF progression.\u003c/p\u003e\n\u003cp\u003eUnderstanding the complexities of lipid metabolism in HFpEF could provide valuable insights for developing targeted treatments. Strategies focusing on modulating lipid uptake, enhancing lipid oxidation, and restoring mitochondrial function may help mitigate disturbances and improve cardiac function in HFpEF patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eTryptophan Metabolism as a Novel Pathway in HFpEF\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTryptophan (Trp), an essential amino acid, serve as a precursor for various biochemical reactions in the human body, including the synthesis of serotonin, glycols, glucocorticoids, and diabetic drugs\u0026nbsp;\u003csup\u003e(25)\u003c/sup\u003e. Trp metabolism is closely associated with various cardiovascular diseases, with increasing research examining its relationship with Heart Failure (HF)\u0026nbsp;\u003csup\u003e(26-28)\u003c/sup\u003e.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTrp metabolism primarily involves pathways such as kynurenine(Kyn), 5-hydroxytryptamine, and indole, generating bioactive compounds that regulate functions like metabolism, inflammation, neurological function and immune responses\u0026nbsp;\u003csup\u003e(29)\u003c/sup\u003e. The gut microbiota significantly affects Trp metabolism by transforming it into various molecules, including indole and its derivatives\u003csup\u003e(30)\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eRecent studies have linked disturbances in the Trp metabolism pathway and the resulting Kyn upregulation to myocardial infarction and atherosclerosis\u0026nbsp;\u003csup\u003e(31, 32)\u003c/sup\u003e. Trp is metabolized predominantly via the kynurenine pathway, which is activated by inflammatory cytokines\u003csup\u003e(33)\u003c/sup\u003e. HFpEF is characterized by chronic low-grade inflammation, which can exacerbate myocardial stress and endothelial dysfunction. The kyn pathway metabolites have pro-inflammatory and oxidative properties that may exacerbate the cardiovascular burden in HFpEF patients. Research indicates that disruptions in tryptophan metabolism are associated with several cardiovascular risk factors, such as hypertension, atherosclerosis, and diabetes, all of which are prevalent in HFpEF populations\u003csup\u003e(25)\u003c/sup\u003e.\u0026nbsp;A study suggested that elevated levels of kynurenine pathway metabolites could serve as biomarkers for worsening heart failure symptoms and poor outcomes in HFpEF patients\u003csup\u003e(18)\u003c/sup\u003e\u003csup\u003e.\u003c/sup\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIn this study, metabolomic analysis revealed significant alterations in the tryptophan metabolic pathway. Further validation using enzyme-linked immunosorbent assay (ELISA) indicated that serum levels of kynurenine and indole-3-acetic acid (IAA) were markedly elevated in patients with HFpEF. These findings suggest that dysregulation of tryptophan metabolism, particularly the increases in kynurenine and IAA, may play a pivotal role in the pathogenesis and progression of HFpEF.\u003c/p\u003e\n\u003cp\u003eKynurenine, a metabolite jointly regulated by the gut microbiota and the immune system, has been extensively documented to be closely associated with vascular inflammation, atherosclerosis, and myocardial hypertrophy\u003csup\u003e(34, 35)\u003c/sup\u003e. Mechanistic studies\u0026nbsp;\u003csup\u003e(36)\u003c/sup\u003ehave demonstrated that kynurenine can activate the aryl hydrocarbon receptor (AHR), thereby promoting myocardial remodeling and fibrosis.\u0026nbsp;Additionally, kynurenine exhibits prominent pro-inflammatory and vasoregulatory effects, further implicating its involvement in the development of cardiovascular diseases\u0026nbsp;\u003csup\u003e(37)\u003c/sup\u003e. Recent research also highlights its role in modulating inflammatory responses in relation to cancer and chronic illnesses, providing multidimensional evidence of its systemic effects\u003csup\u003e(38, 39)\u003c/sup\u003e.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs a tryptophan-derived uremic toxin, indole-3-acetic acid (IAA) accumulates in patients with chronic kidney disease and has been linked to impaired cardiovascular function and increased mortality risk\u003csup\u003e(40)\u003c/sup\u003e. \u0026nbsp;In vivo studies, such as those by Ramya et al. \u003csup\u003e\u0026nbsp;\u003c/sup\u003e\u003csup\u003e(41)\u003c/sup\u003ehave demonstrated that IAA induces cardiotoxicity by activating inflammatory pathways and promoting myocardial fibrosis, subsequently impairing cardiovascular performance. The elevated IAA levels observed in HFpEF patients suggest that it may contribute to disease progression via inflammatory and remodeling pathways, intensifying cardiac dysfunction.\u003c/p\u003e\n\u003cp\u003ePrevious investigations have confirmed associations between kynurenine, IAA, and cardiovascular diseases. The potential pathogenic mechanisms may involve kynurenine’s activation of immune-inflammatory pathways, leading to fibrosis and myocardial remodeling, and IAA’s role as a uremic toxin that alters the cardiovascular microenvironment, inducing inflammation and fibrosis, ultimately impairing cardiac function. These metabolites may exert synergistic or interconnected effects in the pathogenesis of HFpEF, influencing disease onset and progression.\u003c/p\u003e\n\u003cp\u003eDespite existing evidence linking kynurenine and IAA to cardiovascular pathology, their precise mechanistic roles in HFpEF remain to be fully elucidated. Future research employing multi-level in vivo and in vitro approaches, with larger sample sizes and more targeted analyses, is necessary to validate these findings and clarify the underlying pathogenic mechanisms. Such studies could facilitate the development of these metabolites as biomarkers for early diagnosis and disease monitoring, as well as novel therapeutic targets for HFpEF management.\u003c/p\u003e\n\n"},{"header":"5. Conclusion","content":"\u003cp\u003eIn conclusion, metabolomics analyses have identified significant alterations in glycerophospholipid metabolism and the tryptophan pathway in HFpEF, with subsequent validation using enzyme-linked immunosorbent assay (ELISA) confirming elevated levels of kynurenine and indole-3-acetic acid in the serum of HFpEF group . Both glycerophospholipid metabolism and the tryptophan pathway play significant roles in regulating cardiovascular health and disease.\u0026nbsp;\u003c/p\u003e"},{"header":"6. Study Limitations","content":"\u003cp\u003eThere were some shortcomings of the current study to be noted. First, the sample sizes of the HFpEF and HC groups were relatively modest, necessitating a larger, prospective validation cohort to substantiate the identified metabolites. Additionally, the metabolomic profile provides an overview of metabolic disturbances potentially influenced by confounders such as acute illnesses, other disease states, and medication usage. Consequently, it remains uncertain whether the metabolic disturbances identified are exclusively associated with HFpEF syndrome. The majority of recent metabolomics research involving heart failure patients relies on blood samples;however，Hahn et al.\u0026nbsp;\u003csup\u003e[1]\u003c/sup\u003erecently reported that changes in plasma metabolite contents between HFpEF and HFrEF patients may not accurately reflect myocardial metabolic characteristics. This finding underscores the importance of using myocardial tissue directly for metabolomics analysis.\u003c/p\u003e\n\u003cp\u003eOverall, the small sample size in this study could impact the robustness of our results. The metabolome of each individual is highly sensitive to various endogenous and exogenous factors, such as age, sex, diet, environment, geographical location, genetics, and time of day\u0026nbsp;\u003csup\u003e[44]\u003c/sup\u003e\u003csup\u003e(42)\u003c/sup\u003e. Therefore, future studies should focus on the spontaneous screening of HFpEF patients and the validation of these findings. The current results could be further enriched and corroborated by integrating metabolomics research on plasma and feces.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgments\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot Applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study was conducted following the ethical standards outlined in the Declaration of Helsinki (1964) and its subsequent revisions. This experiment has been approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University, and the approval number of this study is 2022B03023-4. All adult subjects provided written informed consent to participate in the study. The individual provided written informed consent to share information about his medical condition and any related images .The Committee\u0026apos;s review ensures that the research meets all relevant ethical standards and local/national guidelines.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflicts of Competing Interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by the Key R\u0026amp;D Program of Xinjiang Uygur Autonomous Region\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;[Grant No. 2022B03023-4].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAM participated in the review and editing. MA, RA performed experiments and analyzed data. DD and MA wrote the manuscript. SA and DD Data curation, Writing- Original draft preparation. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Availability\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll data generated or analyzed during this study are included in this paper. Further enquiries can be directed to the corresponding author.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eClinical trial number\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;Not applicable\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eHahn VS, Petucci C, Kim MS, Bedi KC, Wang HH, Mishra S, et al. Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction. Circulation. 2023;147(15):1147-61.\u003c/li\u003e\n\u003cli\u003eFerro F, Spelat R, Valente C, Contessotto P. Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction. Biomolecules. 2022;12(7):22.\u003c/li\u003e\n\u003cli\u003eHenkens M, Remmelzwaal S, Robinson EL, van Ballegooijen AJ, Aizpurua AB, Verdonschot JAJ, et al. Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. European Journal of Heart Failure. 2020;22(9):1586-97.\u003c/li\u003e\n\u003cli\u003ePieske B, Tsch\u0026ouml;pe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure. 2020;22(3):391-412.\u003c/li\u003e\n\u003cli\u003eAnker SD, Usman MS, Anker MS, Butler J, B\u0026ouml;hm M, Abraham WT, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association and the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. European Journal of Heart Failure. 2023;25(7):936-55.\u003c/li\u003e\n\u003cli\u003eHunter WG, Kelly JP, McGarrah RW, Khouri MG, Craig D, Haynes C, et al. Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. J Am Heart Assoc. 2016;5(8):27.\u003c/li\u003e\n\u003cli\u003eSchiattarella GG, Altamirano F, Tong D, French KM, Villalobos E, Kim SY, et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature. 2019;568(7752):351-+.\u003c/li\u003e\n\u003cli\u003ePalazzuoli A, Tramonte F, Beltrami M. Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature. Biomolecules. 2023;13(1).\u003c/li\u003e\n\u003cli\u003eBekfani T, Bekhite M, Neugebauer S, Derlien S, Hamadanchi A, Nisser J, et al. Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker. Cells. 2022;11(10):13.\u003c/li\u003e\n\u003cli\u003eZordoky BN, Sung MM, Ezekowitz J, Mandal R, Han B, Bjorndahl TC, et al. Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction. PLoS One. 2015;10(5):19.\u003c/li\u003e\n\u003cli\u003eDeng YC, Wang JQ, Zhang AN, Zhu ZJ, Ren SP, Zhang CL, et al. Metabolomics Mechanism and Lignin Response to Laxogenin C, a Natural Regulator of Plants Growth. Int J Mol Sci. 2022;23(6):12.\u003c/li\u003e\n\u003cli\u003eDunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011;6(7):1060-83.\u003c/li\u003e\n\u003cli\u003eMcDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal. 2021;42(48):4901.\u003c/li\u003e\n\u003cli\u003eHahn VS, Knutsdottir H, Luo X, Bedi K, Margulies KB, Haldar SM, et al. Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction. Circulation. 2021;143(2):120-34.\u003c/li\u003e\n\u003cli\u003eBedi KC, Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, et al. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation. 2016;133(8):706-16.\u003c/li\u003e\n\u003cli\u003eLanfear DE, Gibbs JJ, Li J, She RC, Petucci C, Culver JA, et al. Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients. JACC-Heart Fail. 2017;5(11):823-32.\u003c/li\u003e\n\u003cli\u003ePiatek K, Feuerstein A, Zach V, da Conceicao CR, Beblo A, Belyavskiy E, et al. Nitric oxide metabolites: associations with cardiovascular biomarkers and clinical parameters in patients with HFpEF. Esc Heart Failure. 2022;9(6):3961-72.\u003c/li\u003e\n\u003cli\u003eHage C, L\u0026ouml;fgren L, Michopoulos F, Nilsson R, Davidsson P, Kumar C, et al. Metabolomic Profile in HFpEF vs HFrEF Patients. J Card Fail. 2020;26(12):1050-9.\u003c/li\u003e\n\u003cli\u003eDunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):12.\u003c/li\u003e\n\u003cli\u003eLeggat J, Bidault G, Vidal-Puig A. Lipotoxicity: a driver of heart failure with preserved ejection fraction? Clin Sci. 2021;135(19):2265-83.\u003c/li\u003e\n\u003cli\u003ePickens CA, Vazquez AI, Jones AD, Fenton JI. Obesity, adipokines, and C-peptide are associated with distinct plasma phospholipid profiles in adult males, an untargeted lipidomic approach. Sci Rep. 2017;7:14.\u003c/li\u003e\n\u003cli\u003eKojta I, Chacinska M, Blachnio-Zabielska A. Obesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance. Nutrients. 2020;12(5):19.\u003c/li\u003e\n\u003cli\u003eMarcinkiewicz-Siemion M, Ciborowski M, Ptaszynska-Kopczynska K, Szpakowicz A, Lisowska A, Jasiewicz M, et al. LC-MS-based serum fingerprinting reveals significant dysregulation of phospholipids in chronic heart failure. J Pharm Biomed Anal. 2018;154:354-63.\u003c/li\u003e\n\u003cli\u003eRodriguez-Cuenca S, Pellegrinelli V, Campbell M, Oresic M, Vidal-Puig A. Sphingolipids and glycerophospholipids - The \u0026quot;ying and yang\u0026quot; of lipotoxicity in metabolic diseases. Prog Lipid Res. 2017;66:14-29.\u003c/li\u003e\n\u003cli\u003eWyant GA, Moslehi J. Expanding the Therapeutic World of Tryptophan Metabolism. Circulation. 2022;145(24):1799-802.\u003c/li\u003e\n\u003cli\u003eGong X, Sun ZH, Huang ZY, Zhou Q, Yu ZQ, Chen XY, et al. Circulating metabolite profiles to predict response to cardiac resynchronization therapy. BMC Cardiovasc Disord. 2020;20(1):10.\u003c/li\u003e\n\u003cli\u003eMasenga SK, Povia JP, Lwiindi PC, Kirabo A. Recent Advances in Microbiota-Associated Metabolites in Heart Failure. Biomedicines. 2023;11(8):22.\u003c/li\u003e\n\u003cli\u003eRavid JD, Kamel MH, Chitalia VC. Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease. Nat Rev Nephrol. 2021;17(6):402-16.\u003c/li\u003e\n\u003cli\u003eXue C, Li GL, Zheng QX, Gu XY, Shi QM, Su YS, et al. Tryptophan metabolism in health and disease. Cell Metab. 2023;35(8):1304-26.\u003c/li\u003e\n\u003cli\u003eZhang J, Zhu SW, Ma N, Johnston LJ, Wu CD, Ma X. Metabolites of microbiota response to tryptophan and intestinal mucosal immunity: A therapeutic target to control intestinal inflammation. Med Res Rev. 2021;41(2):1061-88.\u003c/li\u003e\n\u003cli\u003eKowalik K, Miekus N, Baczek T. Small Molecules Originated from Tryptophan and their Clinical Significance as Potential Biomarkers. Comb Chem High Throughput Screen. 2022;25(11):1809-17.\u003c/li\u003e\n\u003cli\u003eLaurans L, Venteclef N, Haddad Y, Chajadine M, Alzaid F, Metghalchi S, et al. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nat Med. 2018;24(8):1113-+.\u003c/li\u003e\n\u003cli\u003eLiu G, Chen S, Zhong J, Teng KL, Yin YL. Crosstalk between Tryptophan Metabolism and Cardiovascular Disease, Mechanisms, and Therapeutic Implications. Oxidative Med Cell Longev. 2017;2017:5.\u003c/li\u003e\n\u003cli\u003ePaeslack N, Mimmler M, Becker S, Gao ZL, Khuu MP, Mann A, et al. Microbiota-derived tryptophan metabolites in vascular inflammation and cardiovascular disease. Amino Acids. 2022;54(10):1339-56.\u003c/li\u003e\n\u003cli\u003eWang YH, Song J, Yu K, Nie D, Zhao CC, Jiao LP, et al. Indoleamine 2,3-Dioxygenase 1 Deletion-Mediated Kynurenine Insufficiency Inhibits Pathological Cardiac Hypertrophy. Hypertension. 2023;80(10):2099-111.\u003c/li\u003e\n\u003cli\u003eShi BZ, Zhang XY, Song ZY, Dai ZH, Luo K, Chen B, et al. Targeting gut microbiota-derived kynurenine to predict and protect the remodeling of the pressure-overloaded young heart. Sci Adv. 2023;9(28):14.\u003c/li\u003e\n\u003cli\u003eWang YT, Liu HZ, McKenzie G, Witting PK, Stasch JP, Hahn M, et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med. 2010;16(3):279-U72.\u003c/li\u003e\n\u003cli\u003eAdams S, Braidy N, Bessesde A, Brew BJ, Grant R, Teo C, et al. The Kynurenine Pathway in Brain Tumor Pathogenesis. Cancer Res. 2012;72(22):5649-57.\u003c/li\u003e\n\u003cli\u003eCervenka I, Agudelo LZ, Ruas JL. Kynurenines: Tryptophan\u0026apos;s metabolites in exercise, inflammation, and mental health. Science. 2017;357(6349):8.\u003c/li\u003e\n\u003cli\u003eNayak S, Boopathi S, Chandrasekar M, Panda SP, Manikandan K, Chitra V, et al. Indole-3-acetic acid exposure leads to cardiovascular inflammation and fibrosis in chronic kidney disease rat model. Food Chem Toxicol. 2024;192:13.\u003c/li\u003e\n\u003cli\u003eNayak S, Boopathi S, Chandrasekar M, Yamini B, Chitra V, Almutairi BO, et al. Indole-3 acetic acid induced cardiac hypertrophy in Wistar albino rats. Toxicol Appl Pharmacol. 2024;486:12.\u003c/li\u003e\n\u003cli\u003eMiao XL, Chen JP, Su YY, Luo JY, He Y, Ma J, et al. Plasma metabolomic analysis reveals the therapeutic effects of Jiashen tablets on heart failure. Front Cardiovasc Med. 2022;9:15.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Table","content":"\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" width=\"509\" height=\"735\"\u003e\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"HFpEF, metabolomics, tryptophan metabolism, indole, kynurenine, biomarker","lastPublishedDoi":"10.21203/rs.3.rs-7082748/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7082748/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e\u003cp\u003eHeart failure with preserved ejection fraction (HFpEF) is a complex condition linked to metabolic disturbances. This study aimed to identify plasma metabolic signatures in HFpEF patients using untargeted metabolomic profiling.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e\u003cp\u003eWe analyzed data from 30 HFpEF patients and 30 matched healthy controls. Untargeted metabolomic profiling via UHPLC-MS/MS was conducted on venous blood to identify metabolic differences. Initial analyses included principal component analysis (PCA), partial least squares-discriminant analysis (PLS-DA), and hierarchical clustering to detect differing compound groups. Receiver operating characteristic (ROC) curve analysis and pathway enrichment were performed to identify dysregulated genes. Finally, enzyme-linked immunosorbent assay (ELlSA) was used to validate the serum levels of selected metabolites.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e\u003cp\u003eA total of 124 significantly different metabolites were identified (VIP\u0026thinsp;\u0026gt;\u0026thinsp;1.0, FC\u0026thinsp;\u0026gt;\u0026thinsp;1.2 or \u0026lt;\u0026thinsp;0.833, P\u0026thinsp;\u0026lt;\u0026thinsp;0.05). Lipids and lipid-like molecules were notably altered in HFpEF patients. KEGG enrichment analysis indicated these metabolites were primarily involved in tryptophan metabolism. Hierarchical clustering showed distinct compound levels between groups. ROC curve analysis revealed PC 18:1\u0026ndash;20:5 (AUC: 0.833) and PC 18:1\u0026ndash;18:1 (AUC: 0.824) as key metabolites. ELlSA validation confirmed that serum Kynurenine and IAA levels were significantly elevated in HFpEF patients compared to HCs (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05).\u003c/p\u003e","manuscriptTitle":"Untargeted Metabolomics Unveils Metabolic Biomarkers in HFpEF","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-07-23 02:41:16","doi":"10.21203/rs.3.rs-7082748/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"472aff2f-3958-476d-a6c6-eb7191454d45","owner":[],"postedDate":"July 23rd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-08-13T15:38:42+00:00","versionOfRecord":[],"versionCreatedAt":"2025-07-23 02:41:16","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7082748","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7082748","identity":"rs-7082748","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}